How clinical practice is changing the rules: the sunitinib 2/1 schedule in metastatic renal cell carcinoma.

about

Sunitinib in the treatment of renal cell carcinoma: an update on recent evidence.

P2860

Q52319542-549D2261-82C7-40B6-9F8E-E17CF8DA4A56

P2860

How clinical practice is changing the rules: the sunitinib 2/1 schedule in metastatic renal cell carcinoma.

Item

http://www.wikidata.org/entity/Q39065451

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

How clinical practice is chang ...... tastatic renal cell carcinoma.

@en

How clinical practice is chang ...... tastatic renal cell carcinoma.

@nl

type

Item

label

How clinical practice is chang ...... tastatic renal cell carcinoma.

@en

How clinical practice is chang ...... tastatic renal cell carcinoma.

@nl

prefLabel

How clinical practice is chang ...... tastatic renal cell carcinoma.

@en

How clinical practice is chang ...... tastatic renal cell carcinoma.

@nl

P1476

How clinical practice is chang ...... tastatic renal cell carcinoma.

@en

P2093

Camillo Porta

http://www.w3.org/2001/XMLSchema#string

James Larkin

http://www.w3.org/2001/XMLSchema#string

Jochen Casper

http://www.w3.org/2001/XMLSchema#string

Manuela Schmidinger

http://www.w3.org/2001/XMLSchema#string

Marine Gross Goupil

http://www.w3.org/2001/XMLSchema#string

Sergio Bracarda

http://www.w3.org/2001/XMLSchema#string

Sylvie Negrier

http://www.w3.org/2001/XMLSchema#string

P2860

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables

Outcomes in patients with metastatic renal cell cancer treated with individualized sunitinib therapy: correlation with dynamic microbubble ultrasound data and review of the literature.

Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer.

Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial.

The efficacy and safety of sunitinib in korean patients with advanced renal cell carcinoma: high incidence of toxicity leads to frequent dose reduction.

Pazopanib versus sunitinib in metastatic renal-cell carcinoma.

Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis.

Population Pharmacokinetic/Pharmacodynamic Modeling of Sunitinib by Dosing Schedule in Patients with Advanced Renal Cell Carcinoma or Gastrointestinal Stromal Tumor

P304

227-233

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/14737140.2017.1276830

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Bernard Escudier

P577

2017-01-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28044472

http://www.w3.org/2001/XMLSchema#string

How clinical practice is changing the rules: the sunitinib 2/1 schedule in metastatic renal cell carcinoma.

about

P2860

P2860

How clinical practice is changing the rules: the sunitinib 2/1 schedule in metastatic renal cell carcinoma.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698